Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Tharcila V. Chaves, Bob Wilffert & Zila M. Sanchez. (2020) The use of ketamine to cope with depression and post-traumatic stress disorder: A qualitative analysis of the discourses posted on a popular online forum. The American Journal of Drug and Alcohol Abuse 46:5, pages 613-624.
Read now
Read now
Eric J. Lenze, Nuri B. Farber, Evan Kharasch, Julie Schweiger, Michael Yingling, John Olney & John W. Newcomer. (2016) Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial. The World Journal of Biological Psychiatry 17:3, pages 230-238.
Read now
Read now
Udo Bonnet. (2015) Long-Term Ketamine Self-Injections in Major Depressive Disorder: Focus on Tolerance in Ketamine’s Antidepressant Response and the Development of Ketamine Addiction. Journal of Psychoactive Drugs 47:4, pages 276-285.
Read now
Read now
Articles from other publishers (41)
Anastasiya Zaytseva, Evelina Bouckova, McKennon J Wiles, Madison H Wustrau, Isabella G Schmidt, Hadassah Mendez-Vazquez, Latika Khatri & Seonil Kim. (2023) Ketamine’s rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors. eLife 12.
Crossref
Crossref
Astrid M. Cardona-Acosta & Carlos A. Bolaños-Guzmán. (2023) Role of the mesolimbic dopamine pathway in the antidepressant effects of ketamine. Neuropharmacology 225, pages 109374.
Crossref
Crossref
Miriam Marguilho, Inês Figueiredo & Pedro Castro-Rodrigues. (2022) A unified model of ketamine’s dissociative and psychedelic properties. Journal of Psychopharmacology 37:1, pages 14-32.
Crossref
Crossref
Brandon Richardson, Andrew MacPherson & Francis Bambico. (2022) Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments. Brain, Behavior, & Immunity - Health 26, pages 100554.
Crossref
Crossref
Yazen Alnefeesi, David Chen-Li, Ella Krane, Muhammad Youshay Jawad, Nelson B. Rodrigues, Felicia Ceban, Joshua D. Di Vincenzo, Shakila Meshkat, Roger C.M. Ho, Hartej Gill, Kayla M. Teopiz, Bing Cao, Yena Lee, Roger S. McIntyre & Joshua D. Rosenblat. (2022) Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. Journal of Psychiatric Research 151, pages 693-709.
Crossref
Crossref
Rebecca L Dean, Claudia Hurducas, Keith Hawton, Styliani Spyridi, Philip J Cowen, Sarah Hollingsworth, Tahnee Marquardt, Annabelle Barnes, Rebecca Smith, Rupert McShane, Erick H Turner & Andrea Cipriani. (2021) Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database of Systematic Reviews 2021:11.
Crossref
Crossref
Bruce Edward Jones. 2021. Remington. Remington
719
733
.
Sonalika A. Bhattaccharjee, Kevin S. Murnane & Ajay K. Banga. (2020) Transdermal delivery of breakthrough therapeutics for the management of treatment-resistant and post-partum depression. International Journal of Pharmaceutics 591, pages 120007.
Crossref
Crossref
Israel Garcia-Carachure, Francisco J. Flores-Ramirez, Samuel A. Castillo, Anapaula Themann, Miguel A. Arenivar, Joshua Preciado-Piña, Arturo R. Zavala, Mary Kay Lobo & Sergio D. Iñiguez. (2020) Enduring effects of adolescent ketamine exposure on cocaine- and sucrose-induced reward in male and female C57BL/6 mice. Neuropsychopharmacology 45:9, pages 1536-1544.
Crossref
Crossref
Natalia Gass, Robert Becker, Jonathan Reinwald, Alejandro Cosa-Linan, Markus Sack, Wolfgang Weber-Fahr, Barbara Vollmayr & Alexander Sartorius. (2019) Differences between ketamine’s short-term and long-term effects on brain circuitry in depression. Translational Psychiatry 9:1.
Crossref
Crossref
Sanya Virani, Navjot Brainch, Camila Albuquerque, Souparno Mitra, Maria Bodic & Lama Bazzi. (2018) Exploring the Role of Ketamine in Maintaining the Antidepressant Response. Psychiatric Annals 48:9, pages 437-446.
Crossref
Crossref
J. H. Kwon, W. S. Sim, J. P. Hong, I. S. Song & J. Y. Lee. (2018) Intravenous ketamine infusion for a patient with treatment-resistant major depression: a 10-month follow-up. Journal of Clinical Pharmacy and Therapeutics 43:4, pages 581-583.
Crossref
Crossref
Natalia Gass, Robert Becker, Markus Sack, Adam J. Schwarz, Jonathan Reinwald, Alejandro Cosa-Linan, Lei Zheng, Christian Clemm von Hohenberg, Dragos Inta, Andreas Meyer-Lindenberg, Wolfgang Weber-Fahr, Peter Gass & Alexander Sartorius. (2018) Antagonism at the NR2B subunit of NMDA receptors induces increased connectivity of the prefrontal and subcortical regions regulating reward behavior. Psychopharmacology 235:4, pages 1055-1068.
Crossref
Crossref
Shuken Boku, Shin Nakagawa, Hiroyuki Toda & Akitoyo Hishimoto. (2018) Neural basis of major depressive disorder: Beyond monoamine hypothesis. Psychiatry and Clinical Neurosciences 72:1, pages 3-12.
Crossref
Crossref
Nuri B. Farber. 2019. Antidepressants. Antidepressants
287
305
.
Gislaine Z. Réus, Lutiana R. Simões, Gabriela D. Colpo, Giselli Scaini, Jean P. Oses, Jaqueline S. Generoso, Alan R. Prossin, Rima Kaddurah-Daouk, João Quevedo & Tatiana Barichello. (2017) Ketamine potentiates oxidative stress and influences behavior and inflammation in response to lipolysaccharide (LPS) exposure in early life. Neuroscience 353, pages 17-25.
Crossref
Crossref
Yu-Jhen Huang, Hsien-Yuan Lane & Chieh-Hsin Lin. (2017) New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity. Neural Plasticity 2017, pages 1-11.
Crossref
Crossref
Leorey N. Saligan, David A. Luckenbaugh, Elizabeth E. Slonena, Rodrigo Machado-Vieira & Carlos A. ZarateJr.Jr.. (2016) An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. Journal of Affective Disorders 194, pages 115-119.
Crossref
Crossref
Gislaine Z. Réus, Helena M. Abelaira, Talita Tuon, Stephanie E. Titus, Zuleide M. Ignácio, Ana Lúcia S. Rodrigues & João Quevedo. 2016. Ion Channels as Therapeutic Targets, Part A. Ion Channels as Therapeutic Targets, Part A
169
202
.
Mitsumasa Kurita, Aintzane García-Bea & Javier González-Maeso. 2016. The Medical Basis of Psychiatry. The Medical Basis of Psychiatry
601
654
.
Sara Costi, Nicholas T. Van Dam & James W. Murrough. (2015) Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders. Current Behavioral Neuroscience Reports 2:4, pages 216-225.
Crossref
Crossref
Caroline Caddy, Ben H Amit, Tayla L McCloud, Jennifer M Rendell, Toshi A Furukawa, Rupert McShane, Keith Hawton & Andrea Cipriani. (2015) Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database of Systematic Reviews.
Crossref
Crossref
R. Rajkumar, J. Fam, E.Y.M. Yeo & G.S. Dawe. (2015) Ketamine and suicidal ideation in depression: Jumping the gun?. Pharmacological Research 99, pages 23-35.
Crossref
Crossref
Alana Iglewicz, Katherine Morrison, Richard A. Nelesen, Tingting Zhan, Boris Iglewicz, Nathan Fairman, Jeremy M. Hirst & Scott A. Irwin. (2015) Ketamine for the Treatment of Depression in Patients Receiving Hospice Care: A Retrospective Medical Record Review of Thirty-One Cases. Psychosomatics 56:4, pages 329-337.
Crossref
Crossref
Caoimhe M. Coyle & Keith R. Laws. (2015) The use of ketamine as an antidepressant: a systematic review and meta-analysis. Human Psychopharmacology: Clinical and Experimental 30:3, pages 152-163.
Crossref
Crossref
Ou Sha, Yue Hao, Eric Cho & Li Zhou. 2015. Ketamine. Ketamine
13
36
.
Mark J. Niciu, David A. Luckenbaugh, Dawn F. Ionescu, Erica M. Richards, Jennifer L. Vande Voort, Elizabeth D. Ballard, Nancy E. Brutsche, Maura L. Furey & Carlos A. ZarateJrJr. (2015) Ketamine’s Antidepressant Efficacy is Extended for at Least Four Weeks in Subjects with a Family History of an Alcohol Use Disorder. International Journal of Neuropsychopharmacology 18:1.
Crossref
Crossref
Arpan Dutta, Shane McKie & J.F. William Deakin. (2015) Ketamine and other potential glutamate antidepressants. Psychiatry Research 225:1-2, pages 1-13.
Crossref
Crossref
G. Flores, O. Ibañez-Sandoval, A.B. Silva-Gómez, I. Camacho-Abrego, A. Rodríguez-Moreno & J.C. Morales-Medina. (2014) Neonatal olfactory bulbectomy enhances locomotor activity, exploratory behavior and binding of NMDA receptors in pre-pubertal rats. Neuroscience 259, pages 84-93.
Crossref
Crossref
Mark J. NiciuIoline D. HenterDavid A. LuckenbaughCarlos A. ZarateJr.Jr. & Dennis S. Charney. (2014) Glutamate Receptor Antagonists as Fast-Acting Therapeutic Alternatives for the Treatment of Depression: Ketamine and Other Compounds. Annual Review of Pharmacology and Toxicology 54:1, pages 119-139.
Crossref
Crossref
Eric M. Parise, Lyonna F. Alcantara, Brandon L. Warren, Katherine N. Wright, Roey Hadad, Omar K. Sial, Kyle G. Kroeck, Sergio D. Iñiguez & Carlos A. Bolaños-Guzmán. (2013) Repeated Ketamine Exposure Induces an Enduring Resilient Phenotype in Adolescent and Adult Rats. Biological Psychiatry 74:10, pages 750-759.
Crossref
Crossref
Natalie Katalinic, Rosalyn Lai, Andrew Somogyi, Philip B Mitchell, Paul Glue & Colleen K Loo. (2013) Ketamine as a new treatment for depression: A review of its efficacy and adverse effects. Australian & New Zealand Journal of Psychiatry 47:8, pages 710-727.
Crossref
Crossref
Mario Catena-Dell'Osso, Andrea Fagiolini, Francesco Rotella, Stefano Baroni & Donatella Marazziti. (2013) Glutamate system as target for development of novel antidepressants. CNS Spectrums 18:4, pages 188-198.
Crossref
Crossref
Sarah M. Szymkowicz, Nora Finnegan & Roman M. Dale. (2013) A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. Journal of Affective Disorders 147:1-3, pages 416-420.
Crossref
Crossref
Marije aan het Rot, Carlos A. ZarateJr.Jr., Dennis S. Charney & Sanjay J. Mathew. (2012) Ketamine for Depression: Where Do We Go from Here?. Biological Psychiatry 72:7, pages 537-547.
Crossref
Crossref
Dan J SteinHarish KalraOlivia DeanSeetal DoddMichael Berk. 2012. Antidepressants and Major Depressive Disorder. Antidepressants and Major Depressive Disorder
94
107
.
Blynn G. Bunney & William E. Bunney. (2011) Rapid-acting antidepressant strategies: mechanisms of action. The International Journal of Neuropsychopharmacology 15:05, pages 695-713.
Crossref
Crossref
Claudia Grott ZanicottiDavid PerezPaul Glue. (2012) Mood and Pain Responses to Repeat Dose Intramuscular Ketamine in a Depressed Patient with Advanced Cancer. Journal of Palliative Medicine 15:4, pages 400-403.
Crossref
Crossref
Sanjay J. Mathew, Asim Shah, Kyle Lapidus, Crystal Clark, Noor Jarun, Britta Ostermeyer & James W. Murrough. (2012) Ketamine for Treatment-Resistant Unipolar Depression. CNS Drugs 26:3, pages 189-204.
Crossref
Crossref
Kenji Hashimoto. (2011) The role of glutamate on the action of antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35:7, pages 1558-1568.
Crossref
Crossref
Sherry M. Zakhary, Diana Ayubcha, Farah Ansari, Kiran Kamran, Mehwish Karim, Joerg R. Leheste, Judith M. Horowitz & German Torres. (2010) A behavioral and molecular analysis of ketamine in zebrafish. Synapse 65:2, pages 160-167.
Crossref
Crossref